. Author manuscript; available in PMC: 2022 Aug 1.

Published in final edited form as: Am J Surg Pathol. 2021 Aug 1;45(8):1075–1081. doi: 10.1097/PAS.0000000000001647

Table 2.

Prognostic Effects by Factors among Stage 4S Patients with Favorable “Genotype-IHC-Phenotype” Tumors^* (N=147)

Factor	N	3-year EFS±SE(%)	3-year OS±SE (%)	Log-rank test p-value
DNA Index
Hyperdiploid	96	92.4 ± 3.2	97.9 ± 1.8	EFS: 0.0138
Diploid	24	73.9 ± 9.8	82.1 ± 8.4	OS: 0.0037
ND	27
Age
≥2 Months	54	80.5 ± 6.6	88.4 ± 5.3	EFS: 0.0163
>2 Months	93	93.0 ± 3.1	97.4 ± 1.9	OS: 0.0172
Symptomatic
Yes	40	82.1 ± 7.0	87.2 ± 6.1	EFS: 0.1106
No	107	90.8 ± 3.4	96.7 ± 2.1	OS: 0.0191
1p/11a LOH
Yes	7	71.4 ± 17.1	100	EFS: 0.0045
No	42	97.6 ± 2.4	100	OS: N/A
ND	98

These tumors had no MYCN amplification, Favorable Histology, no MYC-family protein overexpression, and no nucleolar hypertrophy. IHC: Immunohistochemical; ND: Not determined; LOH: Loss of Heterozygosity; EFS: Event-free survival; OS: Overall survival; SE: standard error.